Chronic Hepatitis B: When First-Line Antiviral Therapy Has Not Achieved Viral Suppression
This protocol applies to patients with chronic hepatitis B who are on a first-line oral nucleos(t)ide analogue — entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) — and have shown a suboptimal virological response, including a plateau in HBV DNA decline or a confirmed virological breakthrough.
Prior treatment — failure condition
First-line therapy with one of the preferred oral agents (ETV, TDF, or TAF) did not achieve the intended targets: undetectable HBV DNA by a PCR-based assay, HBeAg loss and seroconversion, HBsAg loss and seroconversion, and normalization of serum ALT. This protocol defines the next clinical step after that failure.
Treatment goal
The primary objective of the next therapeutic step is to achieve undetectable HBV DNA.
Next-step approach (partial overview)
Before modifying therapy, the protocol calls for assessing adherence and increasing the frequency of HBV DNA monitoring. Where appropriate, resistance testing is considered. Once adherence is confirmed, an antiviral change — which may be a switch or an add-on — is guided by the specific agent that was previously used. The complete decision pathway is available in the full structured protocol.
References
DOI: 10.1097/HEP.0000000000001549
- In all cases of suboptimal response, the initial steps include evaluation and reinforcement of adherence, more frequent follow-up of HBV DNA levels to establish pattern and consideration of resistance testing (particularly if the individual meets criteria for virologic breakthrough).
- Once adherence confirmed, if a plateau or virological breakthrough is determined, consideration of an antiviral change should be considered.
- In most cases, a switch of antiviral is preferred (lower pill burden) but add-on therapy can also be considered.
- HBV DNA levels every 3 months until undetectable, then every 6 months.
View source ↗